TargetMol

Zabicipril

Product Code:
 
TAR-T68171
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T68171-1mg1mg£295.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68171-5mg5mg£624.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68171-10mg10mg£860.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68171-25mg25mg£1,243.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68171-50mg50mg£1,653.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68171-100mg100mg£2,199.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Zabicipril is a novel orally available angiotensin-converting enzyme inhibitor, a prodrug with antihypertensive activity following in vivo de-esterification.
CAS:
83059-56-7
Formula:
C23H32N2O5
Molecular Weight:
416.51
Pathway:
Endocrinology/Hormones
Purity:
0.9831
SMILES:
C([C@@H](N[C@H](C(OCC)=O)CCC1=CC=CC=C1)C)(=O)N2[C@H](C(O)=O)C3(CCC2(CC3)[H])[H]
Target:
RAAS

References

Naeije R, et al. Systemic and renal haemodynamic effects of angiotensin converting enzyme inhibition by zabicipril in young and in old normal men. Eur J Clin Pharmacol. 1993;44(1):35-9.